1 week Ago By Defense World Staff
Travere Therapeutics, Inc. ( NASDAQ:TVTX – Free Report ) – Research analysts at Wedbush reduced their FY2028 earnings per share (EPS) estimates for Travere Therapeutics in a report released on Thursday, January 23rd. Wedbush analyst L.
Chico now forecasts that the company will earn $3.79 per share for the year, down from their previous estimate of $3.91.
Wedbush has a “Outperform” rating and a $25.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.
92) per share. TVTX has been the topic of several other research reports. Cantor Fitzgerald assumed coverage on Travere Therapeutics in a research note on Friday, January 10th.
They issued an “overweight” rating on the stock. Barclays upped their price objective on Travere Therapeutics from $18.00 to $20.
00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Piper Sandler upped their price objective on Travere Therapeutics from $12.00 to $22.
00 and gave the company a “neutral” rating in a research note on Thursday, November 14th. Canaccord Genuity Group dropped their price objective on Travere Therapeutics from $23.00 to $22.
00 and set a “buy” rating on the stock in a research note on Monday, September 30th. Finally, Wells Fargo & Company upgraded Travere Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $9.00 to $27.
00 in a research note on Monday, October 21st. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.
00. Travere Therapeutics Stock Performance TVTX opened at $20.31 on Friday.
The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.
71. The business’s 50-day simple moving average is $18.33 and its 200 day simple moving average is $14.
91. The firm has a market capitalization of $1.59 billion, a PE ratio of -4.
46 and a beta of 0.70. Travere Therapeutics has a 52-week low of $5.
12 and a 52-week high of $21.56. Travere Therapeutics ( NASDAQ:TVTX – Get Free Report ) last released its earnings results on Thursday, October 31st.
The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.
01. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.
75%. The business had revenue of $62.90 million for the quarter, compared to analyst estimates of $60.
87 million. During the same quarter in the prior year, the company posted ($1.17) earnings per share.
Travere Therapeutics’s revenue was up 69.6% on a year-over-year basis. Institutional Investors Weigh In On Travere Therapeutics Large investors have recently modified their holdings of the business.
Aigen Investment Management LP acquired a new stake in shares of Travere Therapeutics in the 3rd quarter valued at $170,000. Oppenheimer & Co. Inc.
acquired a new stake in shares of Travere Therapeutics in the 3rd quarter valued at $673,000. Millennium Management LLC boosted its holdings in shares of Travere Therapeutics by 33.9% in the 2nd quarter.
Millennium Management LLC now owns 2,949,335 shares of the company’s stock valued at $24,244,000 after purchasing an additional 747,406 shares in the last quarter. FMR LLC boosted its holdings in shares of Travere Therapeutics by 27.5% in the 3rd quarter.
FMR LLC now owns 147,416 shares of the company’s stock valued at $2,062,000 after purchasing an additional 31,772 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its holdings in shares of Travere Therapeutics by 30.2% in the 3rd quarter.
Two Sigma Advisers LP now owns 720,400 shares of the company’s stock valued at $10,078,000 after purchasing an additional 167,100 shares in the last quarter. Insider Buying and Selling In related news, Director Roy D. Baynes sold 16,000 shares of the stock in a transaction that occurred on Thursday, January 23rd.
The stock was sold at an average price of $20.00, for a total transaction of $320,000.00.
Following the sale, the director now owns 31,000 shares of the company’s stock, valued at $620,000. This represents a 34.04 % decrease in their ownership of the stock.
The sale was disclosed in a filing with the SEC, which is available through the SEC website . Also, CEO Eric M. Dube sold 10,736 shares of the stock in a transaction that occurred on Wednesday, January 22nd.
The stock was sold at an average price of $19.46, for a total value of $208,922.56.
Following the sale, the chief executive officer now directly owns 351,239 shares in the company, valued at $6,835,110.94. This represents a 2.
97 % decrease in their position. The disclosure for this sale can be found here . Insiders have sold 62,143 shares of company stock valued at $1,167,512 over the last 90 days.
3.75% of the stock is owned by corporate insiders. Travere Therapeutics Company Profile ( Get Free Report ) Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases.
Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Further Reading Five stocks we like better than Travere Therapeutics Basic Materials Stocks Investing Bloom Energy: Powering the Future With Decentralized Energy What is the Euro STOXX 50 Index? Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today Why Traders Are Buying the Dip on Johnson & Johnson Stock Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
